Noortje Verschoor

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Venues

Breast cancer research and treatment

NPJ breast cancer

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Noortje Verschoor, Manouk K Bos, Ingeborg E de Kruijff, Mai N Van, Jaco Kraan, Jan C Drooger, Johanna M Zuetenhorst, Saskia M Wilting, Stefan Sleijfer, Agnes Jager, John W M Martens
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. Breast cancer research and treatment 205 (1) (2024)
Noortje Verschoor, Manouk K Bos, Ingeborg E de Kruijff, Mai N Van, Jaco Kraan, Jan C Drooger, Johanna M Zuetenhorst, Saskia M Wilting, Stefan Sleijfer, Agnes Jager, John W M Martens
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. Breast cancer research and treatment 205 (1) (2024)
Noortje Verschoor, Manouk K Bos, Ingeborg E de Kruijff, Mai N Van, Jaco Kraan, Jan C Drooger, Johanna M Zuetenhorst, Saskia M Wilting, Stefan Sleijfer, Agnes Jager, John W M Martens
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. Breast cancer research and treatment 205 (1) (2024)
Noortje Verschoor, Manouk K Bos, Ingeborg E de Kruijff, Mai N Van, Jaco Kraan, Jan C Drooger, Johanna M Zuetenhorst, Saskia M Wilting, Stefan Sleijfer, Agnes Jager, John W M Martens
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. Breast cancer research and treatment (2024)
Noortje Verschoor, Manouk K Bos, Ingeborg E de Kruijff, Mai N Van, Jaco Kraan, Jan C Drooger, Johanna M Zuetenhorst, Saskia M Wilting, Stefan Sleijfer, Agnes Jager, John W M Martens
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. Breast cancer research and treatment 205 (1) (2024)
Noortje Verschoor, Manouk K Bos, Ingeborg E de Kruijff, Mai N Van, Jaco Kraan, Jan C Drooger, Johanna M Zuetenhorst, Saskia M Wilting, Stefan Sleijfer, Agnes Jager, John W M Martens
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial. Breast cancer research and treatment 205 (1) (2024)
Manouk K Bos, Jaco Kraan, Martijn P A Starmans, Jean C A Helmijr, Noortje Verschoor, Maja J A De Jonge, Arjen Joosse, Astrid A M van der Veldt, Peter A W Te Boekhorst, John W M Martens, Stefan Sleijfer, Saskia M Wilting
Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma. Molecular oncology (2024)
Noortje Verschoor, Vanja de Weerd, Mai N Van, Jaco Kraan, Marcel Smid, Joan B Heijns, Jan C Drooger, Johanna M Zuetenhorst, Annemieke van der Padt-Pruijsten, Agnes Jager, Stefan Sleijfer, John W M Martens, Saskia M Wilting
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival. NPJ breast cancer 9 (1) (2023)

Noortje Verschoor.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Noortje Verschoor